Protective effects of erythropoietin on endotoxin-related organ injury in rats

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 5, 2013, Pages 680-686

  Li, Xiu Jiang ^a   Zhang, Guo Xing ^a   Sun, Ni ^a   Sun, Yu ^a   Yang, Li Zhi ^b   Du, Yu Jun ^b  

^a Tumor Hospital of Jilin Province   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

erythropoietin; lipopolysaccharide; multiple organ injury

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ENDOTOXIN; ERYTHROPOIETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROTEIN KINASE B; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; MALE; METABOLISM; MULTIPLE ORGAN FAILURE; PHOSPHORYLATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD UREA NITROGEN; BLOTTING, WESTERN; CREATININE; ENDOTOXINS; ERYTHROPOIETIN; INJECTIONS, INTRAVENOUS; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MULTIPLE ORGAN FAILURE; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886244000     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1180-1     Document Type: Article

References (34)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001,29(7):1303-1310
2. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol, 1978, 93(2):526-618
3. Yoshikawa T, Takano H, Takahashi S, et al. Changes in tissue antioxidant enzyme activities and lipid peroxides in endotoxin-induced multiple organ failure. Circ Shock, 1994,42(1):53-58
4. Thiemermann C, Ruetten H, Wu CC, et al. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol, 1995,116(7):2845-2851
5. Kosai K, Matsumoto K, Funakoshi H, et al. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology, 1999,30(1):151-159
6. Miyaji T, Hu X, Yuen PS, et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int, 2003,64(5):1620-1631
7. Patel NS, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int, 2004,66(6):983-989
8. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med, 2002,8(7):718-724
9. Calapai G, Marciano MC, Corica F, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol, 2000,401(3):349-356
10. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood, 1988,71(2):524-527
11. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int, 1993,44(5):1149-1162
12. Browne JK, Cohen AM, Egrie JC, et al. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol, 1986,51(Pt 1):693-702
13. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol, 1998,5(5):171-176
14. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, con trolled study. Ann Oncol, 1998,9(3):255-260
15. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med, 2002,8(8):495-505
16. Brendt P, Frey U, Adamzik M, et al. Darbepoetin alpha, a long-acting erythropoeitin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-alpha. Shock, 2009,31(1):50-54
17. Spreer A, Gerber J, Hanssen M, et al. No neuroprotective effect of erythropoietin under clinical treatment conditions in a rabbit model of Escherichia coli meningitis. Pediatr Res, 2007,62(6):680-683
18. Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood, 2010,115(21):4264-4272
19. Sølling C. Organ-protective and immunomodulatory effects of erythropoietin-An update on recent clinical trials. Basic Clin Pharmacol Toxicol, 2012,110(2):113-121
20. Jia CS, Chen AJ, Ren LQ. Effects of selenium and vitamin E on myocardial fibrosisin rats fed on grains from Keshan disease endemic area. Jilin Daxue Xuebao (Yixue Ban) (Chinese), 2011,37(3):309-310
21. Hou YC, Chiu WC, Yeh CL, et al. Glutamine modulates lipopolysaccharide- induced activation of NF-kappaB via the Akt/mTOR pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2012,302(1):L174-L183
22. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis, 2003,187(Suppl 2):S364-S369
23. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 2000, 97(19):10526-10531
24. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA, 2004,101(3):823-828
25. Gong H, Wang W, Kwon TH, et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int, 2004,66(2):683-695
26. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem, 2004,279(20):20655-20662
27. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest, 2003,112(7):999-1007
28. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock, 2004,22(1):63-69
29. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int, 1999,55(3):808-820
30. Beleslin-Cokic BB, Cokic VP, Wang L, et al. Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. Cytokine, 2011,54(2):129-135
31. Elliott S, Busse L, Swift S, et al. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant, 2012,27(7):2733-2745
32. Haseyama Y, Sawada K, Oda A, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood, 1999,94(5):1568-1577
33. Carvalho G, Lefaucheur C, Cherbonnier C, et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene, 2005,24(5):737-745
34. Sharples EJ, Thiemermann C, Yaqoob MM. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol, 2006,6(2):184-189